Gilead Sciences (GILD) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

$2.55

Estimate

$2.19

Surprise

+16.2%

Score at report (before → after)

5.4 → 5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Gilead Sciences (GILD) beat the $2.19 estimate with adjusted EPS of $2.55 — a large 16.2% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.4/10) to Sell at 5.3/10 after the report — the engine's score fell despite the beat.

• Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation — benzinga, 2026-10-30
• Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday — benzinga, 2026-10-30

TrendMatrix currently rates GILD Sell at 5.4/10.

4 of the last 4 quarters beat the estimate; this quarter's +16.2% surprise compares with a +8.0% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$165.61

Stop

$157.05

Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - General

Market cap

$205.35B

P/E (fwd)

16.7

52-week range

$114.02–$165.70

Off 52-week high

0.1%

RSI (14)

69

Volume vs avg

1.42×

Score today

5.4/10